US analysts maintained a cautious yet selectively optimistic outlook on October 15, 2026, as reflected in the latest market updates. The day saw 136 price target reductions surpassing 92 increases, underscoring concerns over valuations, earnings growth, and economic uncertainty. However, 20 rating upgrades outpaced 14 downgrades, indicating continued confidence in specific sectors such as energy, financials, healthcare, and technology.
Notable updates included Mizuho lowering A10 Networks' (ATEN) price target to US$30.00 from US$34.00 while maintaining a Neutral rating. Accenture (ACN) received mixed adjustments, with Stifel Nicolaus setting a US$242.00 target, Susquehanna raising its target to US$230.00 from US$210.00, and UBS Group AG setting a US$278.00 target. AECOM (ACM) saw its price target lowered by KeyCorp to US$78.00 from US$79.00, while Royal Bank of Canada adjusted it to US$89.00 from US$90.00.
In the healthcare sector, Alnylam Pharmaceuticals (ALNY) was initiated with a Buy rating and a US$354.00 price target by UBS Group AG. Alphabet (GOOG) and (GOOGL) both had their price targets raised to US$425.00 from US$420.00 by JPMorgan Chase & Co., which maintained an Overweight rating. Meanwhile, AngloGold Ashanti (AU) was initiated with a Reduce rating and a US$104.00 price target by Goldman Sachs.
Bank of America (BAC) experienced multiple adjustments, with Barclays lowering its target to US$68.00 from US$72.00 and Citigroup reducing it to US$60.00 from US$66.00. However, Robert W. Baird upgraded its rating to Outperform with a US$62.00 price target. The day also saw several other significant updates, including upgrades for Arcutis Biotherapeutics (ARQT) and downgrades for Albertsons Companies (ACI).